Chinese english Germany Japanese Korea

2,5-Epoxyanthra[2,3-b]oxepin-5(2H)-carboxylic acid, 3,4,7,12-tetrahydro-6,8,10-trihydroxy-2-methyl-7,12-dioxo- (9CI)

2,5-Epoxyanthra[2,3-b]oxepin-5(2H)-carboxylic acid, 3,4,7,12-tetrahydro-6,8,10-trihydroxy-2-methyl-7,12-dioxo- (9CI) Struktur
162797-37-7
CAS-Nr.
162797-37-7
Englisch Name:
2,5-Epoxyanthra[2,3-b]oxepin-5(2H)-carboxylic acid, 3,4,7,12-tetrahydro-6,8,10-trihydroxy-2-methyl-7,12-dioxo- (9CI)
Synonyma:
Paeciloquinone F;2,5-Epoxyanthra[2,3-b]oxepin-5(2H)-carboxylic acid, 3,4,7,12-tetrahydro-6,8,10-trihydroxy-2-methyl-7,12-dioxo- (9CI)
CBNumber:
CB28219129
Summenformel:
C20H14O9
Molgewicht:
398.32
MOL-Datei:
162797-37-7.mol
Request For Quotation

2,5-Epoxyanthra[2,3-b]oxepin-5(2H)-carboxylic acid, 3,4,7,12-tetrahydro-6,8,10-trihydroxy-2-methyl-7,12-dioxo- (9CI) Eigenschaften

Siedepunkt:
782.8±60.0 °C(Predicted)
Dichte
1.798±0.06 g/cm3(Predicted)
pka
2.21±0.40(Predicted)

Sicherheit

2,5-Epoxyanthra[2,3-b]oxepin-5(2H)-carboxylic acid, 3,4,7,12-tetrahydro-6,8,10-trihydroxy-2-methyl-7,12-dioxo- (9CI) Chemische Eigenschaften,Einsatz,Produktion Methoden

2,5-Epoxyanthra[2,3-b]oxepin-5(2H)-carboxylic acid, 3,4,7,12-tetrahydro-6,8,10-trihydroxy-2-methyl-7,12-dioxo- (9CI) Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

2,5-Epoxyanthra[2,3-b]oxepin-5(2H)-carboxylic acid, 3,4,7,12-tetrahydro-6,8,10-trihydroxy-2-methyl-7,12-dioxo- (9CI) Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 3)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
BOC Sciences 1-631-485-4226; 16314854226
 info@bocsci.com United States 14059 65
Zhejiang Huida Biotech Co., LTD 0571-89903882 13626641628
 jiangnan@huidabiotech.com China 3656 58
Zhejiang Huida Biotech Co., LTD 0571-0571-89903882 15990081639
 sunshixuan@huidabiotech.com China 3705 58
  • 2,5-Epoxyanthra[2,3-b]oxepin-5(2H)-carboxylic acid, 3,4,7,12-tetrahydro-6,8,10-trihydroxy-2-methyl-7,12-dioxo- (9CI)
  • Paeciloquinone F
  • 162797-37-7
Copyright 2019 © ChemicalBook. All rights reserved